track injection sites semaglutide How to Inject Your Semaglutide/Tirzepatide (GLP-1 Analogs) track injection sites semaglutide Sites:

Who loses

Medication breakdown Among participants, 75.2% used semaglutide and 19.9% used tirzepatide

Still just the beginning

These findings suggest that BPC 157 promotes tendon healing by enhancing the sensitivity of tendon fibroblasts to growth hormone, thereby amplifying its anabolic effects

Compound Receptors Peak trial weight loss Lean mass as share of loss Semaglutide (Ozempic/Wegovy) GLP-1 ~14.9% (STEP-1, 68 wk) ~39% Tirzepatide (Mounjaro/Zepbound) GLP-1 + GIP ~20.9% (SURMOUNT-1, 72 wk) ~25-40% Retatrutide GLP-1 + GIP + GCGR ~24.2% (Phase 2, 48 wk) Comparable class range Best for understanding the takeaway: the percentage of loss that is lean mass is roughly constant across the class